低分子肝素在经皮冠状动脉腔内成形术及支架术后抗凝疗效分析

目的：观察低分子肝素对经皮冠状动脉腔内成形术（PTCA）及支架植入术（CASI）后早期抗凝的作用。方法：将64例PTCA和支架植入术后患随机分为低分子肝素（LMWH）组与普通肝素组（SH）组，观察两组7天内临床疗效，并发症发生率等。结果：LMWH组无一例出现并发症，及急性心血管事件，SH组4例牙龈出血，2例于12小时内出现血尿。2例导管穿刺部位出现血肿、渗血。两组比较出血并发症有显性差异（P＜0．05），心血管事件发生率无显差异（P＞0．05）。结论：LMWH与SH一样具有较强抗凝作用，能预防PTCA术后急性血栓形成，且出血并发症少。

Analysis of anticoagulation effect of LMWH after percutaneous transluminal coronary angioplasty and stent

Objective:To investigate the anticoagulation effect of LMWH after percutaneous transluminal coronary angioplasty(PTCA) and stent.Methods:sixty-four patients undergoing PTCA and stent were randomly divided into two groups:one group was treated with LMWH,the other with SH.The clinical outcomes and complications were observed within seven days.Results:No complication and acute cardiovascular event occurred in the LMWH group,while in SH group there were four cases suffering gum bleeding,two cases hematuria within twelve hours,and two cases in region punctured by pipes hematoma and seeping blood.There was significant difference in bleeding complications(P <0 05),but no remarkable difference in cardiovascular event occurring rates between the two groups(P>0 05).Conclusion:LMWM has much stronger anticoagulation effect than the SH,and less bleeding complications.LMWM can prevent the acute thrombus after PTCA.